Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
KALA Kala Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: KALA
Price (delayed)
$4.84
Market cap
$31.23M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$7.97
Enterprise value
$21.36M
Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery
Highlights
The EPS rose by 47% year-on-year and by 21% since the previous quarter
KALA's debt is down by 12% YoY
KALA's quick ratio has plunged by 55% YoY and by 39% from the previous quarter
Kala Pharmaceuticals's equity has shrunk by 54% QoQ and by 14% YoY
Key stats
What are the main financial stats of KALA
Market
Valuations
Earnings
Shares outstanding
6.45M
Market cap
$31.23M
Enterprise value
$21.36M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.47
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$39.31M
Net income
-$35.65M
EBIT
-$30.23M
EBITDA
-$29.63M
Free cash flow
-$27.56M
Per share
Balance sheet
Liquidity
EPS
-$7.97
EPS diluted
-$7.97
Free cash flow per share
-$4.34
Book value per share
$0.88
Revenue per share
$0
TBVPS
$7.6
Total assets
$48.25M
Total liabilities
$42.54M
Debt
$32.35M
Equity
$5.71M
Working capital
$22.74M
Debt to equity
5.67
Current ratio
1.99
Quick ratio
1.84
Net debt/EBITDA
0.33
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-65%
Return on equity
-369.3%
Return on invested capital
-154.9%
Return on capital employed
-119.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KALA stock price
How has the Kala Pharmaceuticals stock price performed over time
Intraday
1.68%
1 week
21%
1 month
30.11%
1 year
-29.75%
YTD
-30.26%
QTD
1.68%
Financial performance
How have Kala Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$39.31M
Net income
-$35.65M
Gross margin
N/A
Net margin
N/A
Kala Pharmaceuticals's net income has increased by 10% YoY and by 7% QoQ
KALA's operating income is up by 3.8% YoY and by 2.8% QoQ
Price vs fundamentals
How does KALA's price correlate with its fundamentals
Growth
What is Kala Pharmaceuticals's growth rate over time
Valuation
What is Kala Pharmaceuticals stock price valuation
P/E
N/A
P/B
5.47
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 47% year-on-year and by 21% since the previous quarter
The price to book (P/B) is 71% higher than the 5-year quarterly average of 3.2 and 52% higher than the last 4 quarters average of 3.6
Kala Pharmaceuticals's equity has shrunk by 54% QoQ and by 14% YoY
Efficiency
How efficient is Kala Pharmaceuticals business performance
The ROIC has shrunk by 54% YoY and by 9% QoQ
The return on equity is up by 5% since the previous quarter
The company's return on assets rose by 5% QoQ and by 2.8% YoY
Dividends
What is KALA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KALA.
Financial health
How did Kala Pharmaceuticals financials performed over time
The total assets is 13% more than the total liabilities
KALA's quick ratio has plunged by 55% YoY and by 39% from the previous quarter
KALA's current ratio has shrunk by 53% YoY and by 36% QoQ
The debt to equity has soared by 116% from the previous quarter and by 3.3% YoY
Kala Pharmaceuticals's equity has shrunk by 54% QoQ and by 14% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.